Curian Capital’s Bristol-Myers Squibb BMY Stock Holding History

Curian Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-67,401	Closed	-$4.64M	–	47
2015 Q4	$4.64M	Sell	67,401 -124,341	-65%	-$8.22M	0.34%	60
2015 Q3	$11.4M	Sell	191,742 -100,352	-34%	-$6.37M	0.3%	72
2015 Q2	$19.4M	Sell	292,094 -5,960	-2%	-$393K	0.33%	69
2015 Q1	$19.2M	Buy	298,054 +117,769	+65%	+$7.37M	0.32%	70
2014 Q4	$10.6M	Sell	180,285 -2,961	-2%	-$167K	0.18%	138
2014 Q3	$9.38M	Sell	183,246 -178,244	-49%	-$8.9M	0.17%	152
2014 Q2	$17.5M	Buy	361,490 +54,584	+18%	+$2.69M	0.31%	76
2014 Q1	$15.9M	Sell	306,906 -5,328	-2%	-$284K	0.28%	72
2013 Q4	$16.6M	Buy	312,234 +136,569	+78%	+$6.96M	0.29%	69
2013 Q3	$8.13M	Buy	175,665 +19,153	+12%	+$841K	0.15%	153
2013 Q2	$7M	Buy	+156,512	New	+$6.79M	0.13%	155

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Curian Capital's BMY Position: Q1 2016 in Review

Curian Capital sold out of Bristol-Myers Squibb (BMY) in Q1 2016, closing a stake of 67,401 shares — an estimated $4.64M sold.

Curian Capital first reported a position in BMY in Q2 2013 and held it in 11 quarters. The position peaked at $19.4M in Q2 2015. 1,523 funds tracked by Wall St. Rank hold BMY as of Q1 2016.

Curian Capital reported no remaining Bristol-Myers Squibb position as of Q1 2016 after selling out during the quarter.
Curian Capital sold 67,401 Bristol-Myers Squibb shares in Q1 2016, an estimated $4.64M.
Curian Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 11 quarters.
Curian Capital's Bristol-Myers Squibb position peaked at $19.4M in Q2 2015.
1,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2016.

Based on Curian Capital's 13F filing for Q1 2016.